nach oben

Zeitschrift für Rheumatologie

Erschienen in:

01.11.2013 | Originalien

Medikamentöse Prophylaxe während intensivierter Immunsuppression bei Kindern und Jugendlichen

Teil 2

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ziel einer modernen Rheumatherapie ist eine möglichst gute Kontrolle der Grunderkrankung. Dies wird im Einzelfall durch die Kombination verschiedener Wirkstoffe erzielt. Dabei ergibt sich eine immer umfangreichere Immunsuppression (IS). Im Sinne einer Risikobegrenzung wäre bei intensivierter IS eine standardisierte Überwachung auf immunologische Veränderungen wünschenswert. Dies kann anhand von Checklisten erfolgen (s. Teil 1 „Vorsorgeuntersuchungen während intensivierter Immunsuppression bei Kindern und Jugendlichen“). Eine individuelle Risikostratifizierung der geplanten IS erlaubt eine Vorhersage von Infektionsrisiken und ermöglicht so eine auf den Patienten zugeschnittene Infektionsprophylaxe. Zusätzlich sollte ein standardisiertes Vorgehen betreffend Diagnostik und Therapie bei Fieber unter intensivierter IS vor weiteren Komplikationen schützen.

Marodi L, Casanova LC (2010) Can primary immundeficiencies help to provide insights into infectious risks of therapeutic antibodies? Nat Rev Immunol 10:299–300CrossRefPubMed

Abunin M (2010) An overview of infectious complications in children on new biologic response-modifying agents. Ped Health 4(5):509–517CrossRef

O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency and cancer. N Engl J Med 368:161–170CrossRef

Marodi L, Casanova JL (2010) Primary immundeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. J Allergy Clin Immunol 126(5):910–917CrossRefPubMed

Agarwal S, Cunningham-Rundles C (2009) Autoimmunity in common variable immundeficiency. Curr Allergy Asthma Rep 9(5):347–352CrossRefPubMed

Heijstek MW, Wulffraat NM (2011) EULAR recommendations for vaccination in pediatric paediatric patients with rheumatic diseases. Ann Rheum Dis 70(10):1704–1712CrossRefPubMed

STIKO, 2005 Bulletin (Sonderdruck): Hinweise zu Impfungen für Patienten mit Immundefizienz

Beukelman T, Nivedita M, Ruperto N et al (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63:4465–4482

Mosca M, Tani C, Aringer M et al (2010) European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and observational studies. Ann Rheum Dis 69(7):1269–1274CrossRefPubMed

10.

Doran MF, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293CrossRefPubMed

11.

Beukelman T (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatement. Arthritis Rheum 64(8):2773–2780CrossRefPubMed

12.

Salliot C, Gosse L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analysis of randomised placebo-controlled trails. Ann Rheum Dis 68:25–32CrossRefPubMed

13.

Genovese MC, Bekker P (2004) Combination therapy with etanercept and anakinra in the treatment of rheumatoid arthritis unsuccesfully treated with methotrexate. Arthritis Rheumatism 50(5):1412–1418CrossRefPubMed

14.

Bernatsky S, Suissa S (2007) Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46:1157–1160

15.

Giannini EH (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794–2804CrossRefPubMed

16.

Silverman E (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666CrossRefPubMed

17.

Foeldvari I (2010) Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 37(8):1763–1767CrossRefPubMed

18.

Figueroa JE, Densen P (1991) Infectious disease associated with complement deficiencies. Clin Mirkobiol Rev 4(3):359–395

19.

Malcolm L, Brigden MD (2001) Detection, education and management of the asplenic or hyposplenic patient. Am Fam Physician 63:499–508

20.

Centers of Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (2010) Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 60(3):72–76

21.

Busse PJ, Cunningham-Rundles C (2002) Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109(6):1001–1004CrossRefPubMed

22.

Ehl S (o J) API-Leitlinien: Di George-Syndrom. http://www.immundefekt.de/digeorge.shtml und Wahn V, Roesler J, Seger R API-Leitlinie: Störung der Granulozytenfunktion. http://www.immundefekt.de/granulozyt.shtml

23.

Engelhardt M, Haas PS, Heimpel H, Kern W (2009) Prävention von Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie. Onkopedia Leitlinien. http://www.dgho-onkopedia.de/onkopedia/leitlinien/praevention-von-infektionen

24.

Thoden J (2011) S2k-AWMF-Leitlinie „Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten Patienten“ (Leitlinie 055/006): Dapson als Alternative empfohlen. www.awmf.org/leitlinien/detail/II/055-006.html

25.

Hughes WT (2005) Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 40(1):136–145CrossRefPubMed

26.

Maltezou HC (1997) Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 20(10):879–881CrossRefPubMed

27.

Prasad P (2008) Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer 50(4):896–898CrossRefPubMed

28.

Au K, Strand V (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70:785–791CrossRefPubMed

29.

Vandenbroucke JP, Cats A (1984) Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 11:158–161PubMed

30.

Ginzler EM, Dvorkina O (2002) Infections in systemic lupus erythematosus. In: Wallace DJ, Hahn BH et al (Hrsg) Dubois lupus erythematosus, Chapter 45, 6. Aufl. Lippincott Williams & Wilkins, Philadelphia, S 901–910 und 1312–1313

31.

Pena-Sagredo JL, Farinas MC, Perez-Zafrilla B et al (2009) Non-typhi salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin Exp Rheumatol 27:920–925PubMed

32.

Alexeeva EI (2011) Efficacy and safety of repeated courses of rituximab treatement in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 30:1163–1172CrossRefPubMed

33.

Tesfa D (2011) Late-onset-neutropenia following rituximab therapy in rheumatic diseases. Arthritis Rheum 63(8):2209–2222CrossRefPubMed

34.

Weinblatt M, Goldman A (2007) Selective costimulation modulation using abatacept in patients with rheumatoid arthritis while receiving etanercept. Rheum Dis 66:228–234CrossRef

35.

Smitten AL, Chan KA et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35(3):387–393PubMed

36.

Weng TC, Toh HS (2011) Ibuprofen worsens streptococcus pyogenes soft tissue infections in mice. J Microbiol Immunol Infect 44(6):418–423CrossRefPubMed

37.

Smitten AL, Choi HK, Hochberg MC et al (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57:1431–1438CrossRefPubMed

38.

Greenberg JD, Hochberg MC (2010) Association of methotrexate and tumor necrosis factor antagonists with risk of infections outcomes including opportunistic infections in the CORONNA registry. Ann Rheum Dis 69(2):380–386CrossRefPubMed

39.

Grijalva CG, Griffin RM (2010) Initiation of rheumatoid arthtritis treatments and risk of serious infections. Rheumatology 49:82–90CrossRefPubMed

40.

De Keyser F (2011) Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev 7:77–87CrossRef

41.

Yuhara T, Kashiwagi H (1996) Predicting infection in hospitalized patients with systemic lupus erythematosus. Intern Med 35(8):629–636CrossRefPubMed

42.

Perez F, Fernandez NF (1993) Infection and systemic lupus erythematosus: analysis of a series of 145 patients. Rev Clin Esp 193:105–109

43.

Andrew McLean-Tooke (2009) Methotrexate, rheumatoid arthritis and infection risk – what is the evidence? Rheumatology 48:867–871CrossRef

44.

Ginzler E, Seleznick M (1978) Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21(1):37–44CrossRefPubMed

45.

Takatsu N (2009) Adverse reactions to azathioprine cannot be predicted by thiopurine S methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 24(7):1258–1264CrossRefPubMed

46.

Doherty SD, Hsu S, National Psoriasis Foundation (2008) National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59(2):209–217CrossRefPubMed

47.

Aguado JM, Doblas A, Munoz P (2009) Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 48(9):1276–1284CrossRefPubMed

48.

Screening for Tuberculosis and Tuberculous Infection in High-Risk Populations Recommendations of the Advisory Committee for Elimination of Tuberculosis. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001642.htm

49.

Behnam SM (2005) Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 4(2):189–194PubMed

50.

Ravelli A (1996) Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 128(2):275–278CrossRefPubMed

51.

Dawson T (1992) Pneumocystis carinii pneumonia following cyclosporine A and methotrexate treated rheumatoid arthritis. J Rheumatol 19(6):997PubMed

52.

European Mycophenolate Mofetile Cooperative Study Group (1995) Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345:1321–1325

53.

Azevedo LS (2005) Mycophenolate mofetil may protect against pneumocystis carinii pneumonia in renal transplanted patients. Rev Inst Med Trop Sao Paulo 47(3):143–145CrossRefPubMed

54.

OZ HS (1997) Novel anti-pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect Dis 175:901–904CrossRefPubMed

55.

Mak A, Lau CS (2009) Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology 48:944–952CrossRefPubMed

56.

Lovell DJ (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–1504CrossRefPubMed

57.

Pain EC, McCann LJ (2009) Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics 3:127–139PubMed

58.

Brassard P, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43:717–722CrossRefPubMed

59.

Diel R, Krüger K (2009) Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF-alpha Inhibitoren bei rheumatischen Erkrankungen. Z Rheumatol 68:411–416CrossRefPubMed

60.

Keystone EC (2011) Challenge in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol 38:1234–1243CrossRefPubMed

61.

Winthrop KL, Chang E, Yamashita S, LoBue PA (2009) Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15:1556–1561CrossRefPubMed

62.

Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 60:1884–1894CrossRefPubMed

63.

Koike T, Yamanaka H (2011) Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70:2148–2151CrossRefPubMed

64.

Mohrbacher A (2005) B cell non-Hodgkin’s lymphoma: rituximab safety experience. Arthritis Res Ther 7(Suppl 3):S19–S25CrossRefPubMed

65.

Jung N, Owczarczyk K, Hellmann M et al (2008) Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) 47:932–933

66.

Burr ML, Malaviya AP, Gaston JH et al (2008) Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47:738–739

67.

Horneff G, Schmeling H et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatement with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519–525CrossRefPubMed

68.

Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 11:954–963CrossRefPubMed

69.

Wollheim FA (1984) Acute and long-term complications of corticosteroid pulse therapy. Scand J Rheumatol Suppl 54:27–32CrossRefPubMed

70.

Askling J, Klareskog L et al (2007) Time‐dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66(10):1339–1344CrossRefPubMed

71.

Tony HP, Burmester G (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75CrossRefPubMed

72.

Minden K, Niewerth M, Borte M et al (2007) Immunization in children and adolescents with rheumatic diseases. Z Rheumatol 66(2):111–118CrossRefPubMed

73.

Adam D (2011) Grippeimpfung bei Kindern: Adjuvantierte Vakzine ist hochwirksam und sicher. Dtsch Arztebl 108(48):A-2607/B-2178/C-2150

74.

Banzhoff A, Stoddard JJ (2012) Effective influenza vaccines for children: a critical unmet medical need and a public health priority. Hum Vaccin Immunother 8(3):398–402CrossRefPubMed

75.

Dell’Era L, Corona F, Daleno C et al (2012) Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 30(5):936–940CrossRef

76.

Vesikari T et al (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:1406–1416CrossRefPubMed

77.

STIKO (2012) Influenza: Sollten ältere Menschen grundsätzlich einen adjuvantierten saisonalen Impfstoff gegen Influenza erhalten? Was muss bei der Impfung von Personen mit Autoimmunerkrankungen beachtet werden? (Stand 07.09.2012) www.rki.de

78.

Heiniger U (2000) Inkubationsimpfungen. Monatsschr Kinderheilkd 148:274–283

79.

Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10:307–322CrossRefPubMed

80.

STIKO (2012) Hinweis zur Impfung mit dem Meningokokken-ACWY-Konjugatimpfstoff; Änderung der Empfehlung zur Indikationsimpfung gegen Meningokokken. Epidemiol Bull 32

81.

Farron F, Pelet B (1996) Chronic meningococcemia and IgA deficiency in an adolescent. Arch Pediatr 3(2):149–151CrossRefPubMed

82.

STIKO (2012) Stellungnahme zur Impfung Erwachsener gegen Pneumokokken. Epidemiol Bul 7

83.

STIKO (2002) Zur Hib-Impfung für Patienten mit Asplenie. Epidemiol Bull 10(41)

84.

STIKO (2009) Indikation zur 2. Varizellen-Impfempfehlung. Bulletin 32

85.

Arvin AM (1996) Varizella-zoster virus. Clin Microbiol Rev 9(3):361–381PubMed

86.

Sartori AM (2004) A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis 8(5):259–270CrossRefPubMed

87.

STIKO (2010) zur Masernimpfung bei Ausbruchsgeschehen: Erstveröffentlicht im Epidemiologischen Bulletin 29/2006; überarbeitet nach Veröffentlichung der aktuellen STIKO-Empfehlung zur Masernimpfung bei Erwachsenen (Stand: Juli 2010)

88.

Borte S, Liebert UG, Borte M (2009) Efficacy od measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 48:144–148

89.

Cornely OA (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359CrossRefPubMed

90.

Goldstein MF (2008) Pediatric selective IgM immundeficiency. Clin Dev Immunol [Epub 2008 Nov 24]

91.

Furst DE (2009) Serum immunoglobulins and risk of infection: How low can you go? Semin Arthritis Rheum 39(1):18–29CrossRefPubMed

92.

Planitzer CB, Farcet MR, Ochs HD, Kreil TR (2011) Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. J Med Virol 83(2):305–310CrossRefPubMed

93.

Minowa K (2009) Examination of availability of the criteria for protective therapy against Pneumocystis pneumonia. Nihon Rinsho Meneki Gakkai Kaishi 32(4):256–262CrossRefPubMed

94.

Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue disease: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42:780–789CrossRefPubMed

95.

Nuesch R (1999) Pneumocystis carinii pneumonia in human immundeficiency virus (HIV)-positiv and HIV-negative immuncompromised patients. Clin Infect Dis 29:1519–1523CrossRefPubMed

96.

Sowden E, Carmichael AJ (2004) Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 4(42):1–6CrossRef

97.

Dunne MW, Bozzette S (1999) Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. Lancet 354(9182):891–895CrossRefPubMed

98.

Respaldiza N (2005) Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clin Microbiol Infect 11(12):1012–1015CrossRefPubMed

99.

Piliero P (1990) Functional asplenia in systemic lupus erythematosus. J Rheumatol 7:196–198

100.

Dillon AM (1982) Splenic atrophy in systemic lupus erythematosus. Ann Intern Med 96(1):40–43CrossRefPubMed

101.

Görg C (2003) The small spleen: sonographic patterns of functional hyposplenia or asplenia. J Clin Ultrasound 31(3):152–155CrossRefPubMed

102.

Powsner RA (1998) Scintigraphic functional hyposplenism in amyloidosis. J Nucl Med 39(2):221–223PubMed

103.

Brunkhorst R, Eberhardt OK, Haubnitz M, Brunkhorst FM (2000) Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intensive Care Med 26(Suppl 2):S199–S201PubMed

104.

Williams RC, Harmon ME, Burlingame R (2005) Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 32:454–461PubMed

105.

Stiehm ER, Ochs HD (2004) Immunologic disorders in infants and children (textbook). Saunders, Philadelphia

Titel: Medikamentöse Prophylaxe während intensivierter Immunsuppression bei Kindern und Jugendlichen
Teil 2
Publikationsdatum: 01.11.2013
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 9/2013
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-013-1203-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Medikamentöse Prophylaxe während intensivierter Immunsuppression bei Kindern und Jugendlichen

Teil 2

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2013

Urologische Begleiterkrankungen bei Patienten mit rheumatoider Arthritis

Mitteilungen

Interdisziplinäres Vorgehen bei einem Patienten mit IgG4-assoziiertem Morbus Mikulicz

Update

Intrazelluläre Targets

Sind die Empfehlungen zum Tuberkulosescreening noch zeitgemäß?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin